Indivior Dividendas 2024

Ką daro Indivior?

Indivior PLC is a globally operating company that specializes in the development and marketing of therapies for the treatment of addiction disorders. The company is headquartered in Slough, UK, and employs around 900 people worldwide. Indivior's history dates back to the founding of Reckitt Benckiser Pharmaceuticals in 1994. However, in 2014, the company decided to spin off its pharmaceutical division and continue as an independent company. Since then, Indivior has continuously invested in research and development to develop new and innovative therapies for the treatment of opioid addiction and other addiction disorders. Indivior's business model is based on ensuring comprehensive patient care for those suffering from addiction disorders through close collaboration with health authorities, doctors, and other healthcare professionals. The company relies on a combination of medical therapies and psychosocial support. Indivior operates in various divisions that focus on different aspects of addiction treatment. The key divisions are: - Opioid addiction: Indivior offers various therapies for the treatment of opioid addiction, including Suboxone Film and Sublocade, both based on buprenorphine. - Alcohol addiction: Indivior has also developed a therapy for the treatment of alcohol addiction marketed under the name ALO-02. - Pain therapy: Indivior has also developed a range of pain therapies based on buprenorphine or naloxone. - Research and development: A major focus of Indivior is on researching and developing new therapies for the treatment of addiction disorders. Indivior has also formed partnerships with other companies and organizations in the healthcare industry to improve the care of patients with addiction disorders. This includes collaboration with patient organizations advocating for the interests of patients with addiction disorders. Overall, Indivior has achieved impressive success in developing innovative therapies for the treatment of addiction disorders in recent years. The company has not only strengthened its position as a leading provider of opioid therapies, but also made progress in other areas such as alcohol addiction and pain therapy. However, Indivior has also faced challenges. For example, the company had to address allegations related to the marketing of Suboxone Film and other products. However, Indivior has taken steps to improve its compliance procedures and ensure that its products are marketed in accordance with applicable regulations. Overall, Indivior remains a leading provider of therapies for the treatment of addiction disorders and is committed to improving the quality of life for patients with addiction problems. Indivior yra viena populiariausių įmonių Eulerpool.com svetainėje.